Taurodeoxycholic acid alleviates intestinal inflammation by modulating gut microbiota and TGR5-NF-kappaB axis in DSS-induced colitis
- Int Immunopharmacol. 2026 Feb 1:170:116056. doi: 10.1016/j.intimp.2025.116056.
- 1. Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan 250012, China; Laboratory of Translational Gastroenterology, Qilu Hospital, Shandong University, Jinan 250012, China; Shandong Provincial Clinical Research Center for digestive disease, Qilu Hospital, Shandong University, Jinan 250012, China.
- 2. Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan 250012, China; Laboratory of Translational Gastroenterology, Qilu Hospital, Shandong University, Jinan 250012, China; Shandong Provincial Clinical Research Center for digestive disease, Qilu Hospital, Shandong University, Jinan 250012, China; Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
- 3. Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan 250012, China; Laboratory of Translational Gastroenterology, Qilu Hospital, Shandong University, Jinan 250012, China; Shandong Provincial Clinical Research Center for digestive disease, Qilu Hospital, Shandong University, Jinan 250012, China; Robot Engineering Laboratory for Precise Diagnosis and Therapy of Gastrointestinal Tumor, Qilu Hospital of Shandong University, Jinan 250012, China. Electronic address: [email protected].
- 4. Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan 250012, China; Medical Integration and Practice Center, Shandong University, Jinan 250012, China; Cholestatic Liver Diseases Center and Center for Metabolic Associated Fatty Liver Disease, The First Affiliated Hospital (Southwest Hospital), Third Military Medical University (Army Medical University), Chongqing 400038, China. Electronic address: [email protected].
Taurodeoxycholic acid (TDCA), a metabolite of Cholesterol, has been shown to be able to regulate various inflammatory responses and improve intestinal inflammation. However, its potential to alleviate colitis through modulating the gut microbiota-bile acid axis remains unclear. Mice were simultaneously administered dextran sulfate sodium (DSS) and TDCA via drinking water to estimate the effect of TDCA on colitis. TDCA-treated mice showed markedly relieved DSS-induced colitis. 16S rDNA Sequencing revealed TDCA selectively remodeled the gut microbiota, notably decreasing the abundances of Desulfovibrionaceae_unclassified, Escherichia-Shigella and increasing Akkermansia. Furthermore, the reshaping of the microbial community was functionally characterized by a marked alteration in the gut bile acid profile, specifically a significant increase in secondary bile acids. Fecal microbiota transplantation (FMT) confirmed the protective role of the TDCA-shaped microbiota, which also transferred the reduction of Desulfovibrionaceae_unclassified and the characteristic bile acid profile to recipient mice. Similarly, transplanting feces after TDCA intervention into recipient mice still increased secondary bile acid levels in the gut to a certain extent. Spearman's correlation analysis further solidified the negative correlation between Desulfovibrionaceae_unclassified and secondary bile acids. Mechanistically, the altered bile acid profiles restored the activation of the bile acid receptor TGR5, but not FXR, thereby inhibiting the NF-κB signaling pathway. The essential role of TGR5 was substantiated as its inhibitor, SBI-115, largely abolished the protective effects of TDCA. In conclusion, our findings demonstrate that TDCA alleviates colitis by orchestrating a microbiota-bile acid-TGR5 signaling cascade, positioning it as a promising therapeutic candidate for inflammatory bowel disease.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Others